Zydus Lifesciences is on analysts' radar. The stock rose nearly 2% on Wednesday after reporting mixed fourth-quarter results.

After a record FY25, the drugmaker sees new growth engines in biologics, vaccines, and devices powering expansion in FY26.

The company's net profit was at Rs 1,182 crore, with revenue at Rs 5,633 crore and EBITDA margin rising to 26.7 percent, in ...

ICICI Securities recommended hold rating on Zydus Lifesciences with a target price of Rs 910 in its research report dated May ...

The Subject Expert Committee (SEC) on Haematology has recommended for grant of permission to conduct a Phase-III clinical ...

Zydus Lifesciences Q4 stuns with margin guidance, but brokerages trim targets — stock ends at Rs 890. Should you follow ...

Zydus Lifesciences consolidated net profit slipped about 1 per cent year-on-year (Y-o-Y) to ₹1,171 crore in the March quarter ...

Results: Zydus Lifesciences Q4FY25 net profit dips 1% to Rs 1,244 crore due to exceptional charge; revenue grows 17% to Rs ...

The pharma companys Board has recommended a final dividend of Rs 11 per equity share of face value Rs 1 each, representing a ...

Morgan Stanley believes India's fundamentals remain strong, supported by macro stability, improving terms of trade, declining ...

We are looking at what kind of products, diagnostics or other solutions we can offer to become a well-rounded player in a ...

Ahmedabad-based Zydus Lifesciences Ltd has registered a decline of around 1% in net profit at Rs. 1,170.9 crore during the last quarter of FY25, as compared to Rs. 1,182.3 crore in the same period a ...